---
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263291257.md"
description: "The incoming CEO of GSK, Luke Mills: Achieving the goal of £40 billion in sales by 2031 is feasible, and \"I am confident about it.\""
datetime: "2025-10-29T12:42:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263291257.md)
  - [en](https://longbridge.com/en/news/263291257.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263291257.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/263291257.md) | [English](https://longbridge.com/en/news/263291257.md)


# 

The incoming CEO of GlaxoSmithKline (GSK.N), Luke Mills: The goal of achieving £40 billion in sales by 2031 is feasible, and "I am confident about it."

### 相關股票

- [GSK (GSK.US)](https://longbridge.com/zh-HK/quote/GSK.US.md)

## 相關資訊與研究

- [GSK says bepirovirsen accepted for review in China](https://longbridge.com/zh-HK/news/280965183.md)
- [GSK plc - ViiV completes changes to minority shareholding](https://longbridge.com/zh-HK/news/281310118.md)
- [GSK’s Hepatitis B Drug Bepirovirsen Enters China Regulatory Review as Potential First-in-Class Cure](https://longbridge.com/zh-HK/news/280975279.md)
- [GSK Expands Treasury Stock with Latest Tranche of Share Buybacks](https://longbridge.com/zh-HK/news/281478504.md)
- [Key facts: GSK's depemokimab approved in China; shares trade 50–60](https://longbridge.com/zh-HK/news/281098121.md)